Search

Your search keyword '"Della Corte, Carminia Maria"' showing total 20 results
Start Over Author "Della Corte, Carminia Maria" Publisher mdpi ag
20 results on '"Della Corte, Carminia Maria"'

1. Post-Irradiation Breast Angiosarcoma: All the Possible Treatments and Electrochemotherapy. Case Report and Literature Review

Author

Parisi, Simona, primary, Gambardella, Claudio, additional, Iovino, Francesco, additional, Ruggiero, Roberto, additional, Lucido, Francesco Saverio, additional, Nesta, Giusiana, additional, Tolone, Salvatore, additional, Brusciano, Luigi, additional, Fisone, Francesca, additional, Mongardini, Federico Maria, additional, Cozzolino, Giovanni, additional, Della Corte, Carminia Maria, additional, Napolitano, Stefania, additional, Orditura, Michele, additional, Esposito, Rosetta, additional, and Docimo, Ludovico, additional

Published
2024
Full Text
View/download PDF

2. CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial

Author

Nardone, Valerio, primary, Belfiore, Maria Paola, additional, De Chiara, Marco, additional, De Marco, Giuseppina, additional, Patanè, Vittorio, additional, Balestrucci, Giovanni, additional, Buono, Mauro, additional, Salvarezza, Maria, additional, Di Guida, Gaetano, additional, D’Angiolella, Domenico, additional, Grassi, Roberta, additional, D’Onofrio, Ida, additional, Cimmino, Giovanni, additional, Della Corte, Carminia Maria, additional, Gambardella, Antonio, additional, Morgillo, Floriana, additional, Ciardiello, Fortunato, additional, Reginelli, Alfonso, additional, and Cappabianca, Salvatore, additional

Published
2023
Full Text
View/download PDF

3. A Critical Issue in Lung Cancer Cytology and Small Biopsies: DNA and RNA Extraction from Archival Stained Slides for Biomarker Detection through Real Time PCR and NGS—The Experience in Pathological Anatomy Unit

Author

Zannini, Giuseppa, primary, Tedesco, Ilaria, additional, Cozzolino, Immacolata, additional, Montella, Marco, additional, Clery, Eduardo, additional, Della Corte, Carminia Maria, additional, Morgillo, Floriana, additional, Accardo, Marina, additional, Franco, Renato, additional, and Zito Marino, Federica, additional

Published
2023
Full Text
View/download PDF

4. PATZ1 in Non-Small Cell Lung Cancer: A New Biomarker That Negatively Correlates with PD-L1 Expression and Suppresses the Malignant Phenotype

Author

Lucà, Stefano, primary, Franco, Renato, additional, Napolitano, Antonella, additional, Soria, Valeria, additional, Ronchi, Andrea, additional, Zito Marino, Federica, additional, Della Corte, Carminia Maria, additional, Morgillo, Floriana, additional, Fiorelli, Alfonso, additional, Luciano, Antonio, additional, Palma, Giuseppe, additional, Arra, Claudio, additional, Battista, Sabrina, additional, Cerchia, Laura, additional, and Fedele, Monica, additional

Published
2023
Full Text
View/download PDF

5. Role of Cardiac Biomarkers in Non-Small Cell Lung Cancer Patients

Author

Nardone, Valerio, primary, Reginelli, Alfonso, additional, De Marco, Giuseppina, additional, Natale, Giovanni, additional, Patanè, Vittorio, additional, De Chiara, Marco, additional, Buono, Mauro, additional, Russo, Gaetano Maria, additional, Monti, Riccardo, additional, Balestrucci, Giovanni, additional, Salvarezza, Maria, additional, Di Guida, Gaetano, additional, D’Ippolito, Emma, additional, Sangiovanni, Angelo, additional, Grassi, Roberta, additional, D’Onofrio, Ida, additional, Belfiore, Maria Paola, additional, Cimmino, Giovanni, additional, Della Corte, Carminia Maria, additional, Vicidomini, Giovanni, additional, Fiorelli, Alfonso, additional, Gambardella, Antonio, additional, Morgillo, Floriana, additional, and Cappabianca, Salvatore, additional

Published
2023
Full Text
View/download PDF

6. AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma

Author

Zito Marino, Federica, primary, Della Corte, Carminia Maria, additional, Ciaramella, Vincenza, additional, Erra, Stefania, additional, Ronchi, Andrea, additional, Fiorelli, Alfonso, additional, Vicidomini, Giovanni, additional, Santini, Mario, additional, Scognamiglio, Giosuè, additional, Morgillo, Floriana, additional, Ciardiello, Fortunato, additional, Franco, Renato, additional, and Accardo, Marina, additional

Published
2022
Full Text
View/download PDF

7. Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series

Author

Guerrera, Luigi Pio, primary, Suarato, Gabriella, additional, Napolitano, Rossella, additional, Perrone, Alessandra, additional, Caputo, Vincenza, additional, Ventriglia, Anna, additional, Martini, Giulia, additional, Della Corte, Carminia Maria, additional, Orditura, Michele, additional, Martinelli, Erika, additional, Ciardiello, Fortunato, additional, Montella, Marco, additional, Franco, Renato, additional, Troiani, Teresa, additional, and Napolitano, Stefania, additional

Published
2022
Full Text
View/download PDF

8. Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors

Author

Iacovino, Maria Lucia, primary, Miceli, Chiara Carmen, additional, De Felice, Marco, additional, Barone, Biagio, additional, Pompella, Luca, additional, Chiancone, Francesco, additional, Di Zazzo, Erika, additional, Tirino, Giuseppe, additional, Della Corte, Carminia Maria, additional, Imbimbo, Ciro, additional, De Vita, Ferdinando, additional, and Crocetto, Felice, additional

Published
2022
Full Text
View/download PDF

9. Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data

Author

Sardo, Emilia, primary, Napolitano, Stefania, additional, Della Corte, Carminia Maria, additional, Ciardiello, Davide, additional, Raucci, Antonio, additional, Arrichiello, Gianluca, additional, Troiani, Teresa, additional, Ciardiello, Fortunato, additional, Martinelli, Erika, additional, and Martini, Giulia, additional

Published
2022
Full Text
View/download PDF

10. Head and Neck Squamous Cell Carcinoma in Elderly Patients: Role of Radiotherapy and Chemotherapy

Author

Fasano, Morena, primary, D’Onofrio, Ida, additional, Belfiore, Maria Paola, additional, Angrisani, Antonio, additional, Caliendo, Valentina, additional, Della Corte, Carminia Maria, additional, Pirozzi, Mario, additional, Facchini, Sergio, additional, Caterino, Marianna, additional, Guida, Cesare, additional, Nardone, Valerio, additional, Reginelli, Alfonso, additional, and Cappabianca, Salvatore, additional

Published
2022
Full Text
View/download PDF

11. A Trimodality, Four-Step Treatment including Chemotherapy, Pleurectomy/Decortication and Radiotherapy in Early-Stage Malignant Pleural Mesothelioma: A Single-Institution Retrospective Case Series Study

Author

Vicidomini, Giovanni, primary, Della Corte, Carminia Maria, additional, Noro, Antonio, additional, Di Liello, Raimondo, additional, Cappabianca, Salvatore, additional, Fiorelli, Alfonso, additional, Nardone, Valerio, additional, Messina, Gaetana, additional, Viscardi, Giuseppe, additional, Sangiovanni, Angelo, additional, Monti, Riccardo, additional, Accardo, Marina, additional, Morgillo, Floriana, additional, Ciardiello, Fortunato, additional, Franco, Renato, additional, and Santini, Mario, additional

Published
2021
Full Text
View/download PDF

12. How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma

Author

Martini, Giulia, primary, Ciardiello, Davide, additional, Paragliola, Fernando, additional, Nacca, Valeria, additional, Santaniello, Walter, additional, Urraro, Fabrizio, additional, Stanzione, Maria, additional, Niosi, Marco, additional, Dallio, Marcello, additional, Federico, Alessandro, additional, Selvaggi, Francesco, additional, Della Corte, Carminia Maria, additional, Napolitano, Stefania, additional, Ciardiello, Fortunato, additional, and Martinelli, Erika, additional

Published
2021
Full Text
View/download PDF

14. Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies

Author

Bellastella, Giuseppe, primary, Carbone, Carla, additional, Scappaticcio, Lorenzo, additional, Cirillo, Paolo, additional, Troiani, Teresa, additional, Morgillo, Floriana, additional, Vietri, Maria Teresa, additional, Della Corte, Carminia Maria, additional, De Falco, Vincenzo, additional, Napolitano, Stefania, additional, Maiorino, Maria Ida, additional, De Bellis, Annamaria, additional, and Esposito, Katherine, additional

Published
2021
Full Text
View/download PDF

15. CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial

Author

Valerio Nardone, Maria Paola Belfiore, Marco De Chiara, Giuseppina De Marco, Vittorio Patanè, Giovanni Balestrucci, Mauro Buono, Maria Salvarezza, Gaetano Di Guida, Domenico D’Angiolella, Roberta Grassi, Ida D’Onofrio, Giovanni Cimmino, Carminia Maria Della Corte, Antonio Gambardella, Floriana Morgillo, Fortunato Ciardiello, Alfonso Reginelli, Salvatore Cappabianca, Nardone, Valerio, Belfiore, Maria Paola, DE CHIARA, Marco, DE MARCO, Giuseppina, Patanè, Vittorio, Balestrucci, Giovanni, Buono, Mauro, Salvarezza, Maria, Di Guida, Gaetano, D’Angiolella, Domenico, Grassi, Roberta, D’Onofrio, Ida, Cimmino, Giovanni, DELLA CORTE, Carminia Maria, Gambardella, Antonio, Morgillo, Floriana, Ciardiello, Fortunato, Reginelli, Alfonso, and Cappabianca, Salvatore

Subjects
thoracic imaging, Clinical Biochemistry, cardiac MRI, cardiac CT, NSCLC, radiotherapy
Abstract

Background: Non-small-cell lung cancer (NSCLC) is a common, steady growing lung tumour that is often discovered when a surgical approach is forbidden. For locally advanced inoperable NSCLC, the clinical approach consists of a combination of chemotherapy and radiotherapy, eventually followed by adjuvant immunotherapy, a treatment that is useful but may cause several mild and severe adverse effect. Chest radiotherapy, specifically, may affect the heart and coronary artery, impairing heart function and causing pathologic changes in myocardial tissues. The aim of this study is to evaluate the damage coming from these therapies with the aid of cardiac imaging. Methods: This is a single-centre, prospective clinical trial. Patients with NSCLC who are enrolled will undergo computed tomography (CT) and magnetic resonance imaging (MRI) before chemotherapy 3 months, 6 months, and 9–12 months after the treatment. We expect to enrol 30 patients in 2 years. Conclusions: Our clinical trial will be an opportunity not only to highlight the timing and the radiation dose needed for pathological cardiac tissue changes to happen but will also provide useful data to set new follow-up schedules and strategies, keeping in mind that, more often than not, patients affected by NSCLC may present other heart- and lung-related pathological conditions.

Published
2023
Full Text
View/download PDF

16. Role of Cardiac Biomarkers in Non-Small Cell Lung Cancer Patients

Author

Valerio Nardone, Alfonso Reginelli, Giuseppina De Marco, Giovanni Natale, Vittorio Patanè, Marco De Chiara, Mauro Buono, Gaetano Maria Russo, Riccardo Monti, Giovanni Balestrucci, Maria Salvarezza, Gaetano Di Guida, Emma D’Ippolito, Angelo Sangiovanni, Roberta Grassi, Ida D’Onofrio, Maria Paola Belfiore, Giovanni Cimmino, Carminia Maria Della Corte, Giovanni Vicidomini, Alfonso Fiorelli, Antonio Gambardella, Floriana Morgillo, Salvatore Cappabianca, Nardone, Valerio, Reginelli, Alfonso, De Marco, Giuseppina, Natale, Giovanni, Patanè, Vittorio, De Chiara, Marco, Buono, Mauro, Maria Russo, Gaetano, Monti, Riccardo, Balestrucci, Giovanni, Salvarezza, Maria, Di Guida, Gaetano, D’Ippolito, Emma, Sangiovanni, Angelo, Grassi, Roberta, D’Onofrio, Ida, Belfiore, Maria Paola, Cimmino, Giovanni, DELLA CORTE, Carminia Maria, Vicidomini, Giovanni, Fiorelli, Alfonso, Gambardella, Antonio, Morgillo, Floriana, and Cappabianca, Salvatore

Subjects
cardio-oncology, Clinical Biochemistry, biomarkers, heart, NSCLC, radiotherapy
Abstract

Treatment-induced cardiac toxicity represents an important issue in non-small cell lung cancer (NSCLC) patients, and no biomarkers are currently available in clinical practice. A novel and easy-to-calculate marker is the quantitative analysis of calcium plaque in the coronary, calculated on CT. It is called the Agatston score (or CAD score). At the same time, other potential predictors include cardiac ultrasonography and anamnesis of the patients. Our work aimed to correlate cardiac biomarkers with overall survival (OS) in NSCLC patients. We retrospectively analyzed patients with NSCLC discussed in the Multidisciplinary Tumor Board of our Institute for the present analysis between January 2018 and July 2022. Inclusion criteria were the availability of basal CT imaging of the thorax, cardiac ultrasonography with the calculation of ejection fraction (EF), and complete anamnesis, including assessment of co-pathologies and pharmacological drugs. The clinical data of the patients were retrospectively collected, and the CAD scores was calculated on a CT scan. All of these parameters were correlated with overall survival (OS) with univariate analysis (Kaplan–Meier analysis) and multivariate analysis (Cox regression analysis). Following the above-mentioned inclusion criteria, 173 patients were included in the present analysis. Of those, 120 patients died in the follow-up period (69.6%), and the median overall survival (OS) was 28 months (mean 47.2 months, 95% CI, 36–57 months). In univariate analysis, several parameters that significantly correlated with lower OS were the stage (p < 0.001), the CAD grading (p < 0.001), history of ischemic heart disease (p: 0.034), use of beta blocker drugs (p: 0.036), and cardiac ejection fraction (p: 0.005). In multivariate analysis, the only parameters that remained significant were as follows: CAD score (p: 0.014, OR 1.56, 95% CI: 1.04–1.83), stage (p: 0.016, OR: 1.26, 95% CI: 1.05–1.53), and cardiac ejection fraction (p: 0.011, OR 0.46, 95% CI: 0.25–0.84). Both CAD score and ejection fraction are correlated with survival in NSCLC patients at all stages of the disease. Independently from the treatment choice, a cardiological evaluation is mandatory for patients with NSCLC.

Published
2023
Full Text
View/download PDF

17. Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series

Author

Luigi Pio Guerrera, Gabriella Suarato, Rossella Napolitano, Alessandra Perrone, Vincenza Caputo, Anna Ventriglia, Giulia Martini, Carminia Maria Della Corte, Michele Orditura, Erika Martinelli, Fortunato Ciardiello, Marco Montella, Renato Franco, Teresa Troiani, Stefania Napolitano, Guerrera, Luigi Pio, Suarato, Gabriella, Napolitano, Rossella, Perrone, Alessandra, Caputo, Vincenza, Ventriglia, Anna, Martini, Giulia, Della Corte, Carminia Maria, Orditura, Michele, Martinelli, Erika, Ciardiello, Fortunato, Montella, Marco, Franco, Renato, Troiani, Teresa, and Napolitano, Stefania

Subjects
Health Information Management, Leadership and Management, Health Policy, Foundation One (F1), mixed neuroendocrine/non-neuroendocrine neoplasms, Health Informatics, NGS analysi, MiNEN, gastrointestinal tumor
Abstract

Mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs) refer to heterogenous rare neoplasms constituted of at least a neuroendocrine population—either well-differentiated, or more frequently poorly differentiated—and a non-neuroendocrine population, both accounting for at least 30% of the whole tumor mass. Several studies recently focused on the key genetic and epigenetic changes underlying MiNENs to better understand how they develop, and explore biological similarities among the two components and their pure counterparts. However, their molecular landscape still remains poorly understood. NGS may represent a useful tool to study this orphan disease by detecting the main genetic alterations and possible therapeutic targets. NGS analysis on tissue and/or blood samples through the Foundation One (F1) platform was performed on consecutive samples collected from four patients diagnosed with MiNENs of the gastroenteric tract. Several genetic alterations were shared among samples from the same patients, thus suggesting a common origin between them, although morphology sometimes changed at histopathological evaluation. Common molecular alterations among samples from different patients that had not been previously described to our knowledge were also detected. Finally, it is of the utmost importance to clarify if the maintenance of the 30% cut-off is still essential in defining MiNENs and really manages to include all of the mixed neoplasms.

Published
2022
Full Text
View/download PDF

18. HGF/MET and the Immune System: Relevance for Cancer Immunotherapy

Author

Federica Papaccio, Raimondo Di Liello, Floriana Morgillo, Giuseppe Viscardi, Francesca Sparano, Fortunato Ciardiello, Carminia Maria Della Corte, Giovanna Esposito, Papaccio, Federica, Della Corte, Carminia Maria, Viscardi, Giuseppe, Di Liello, Raimondo, Esposito, Giovanna, Sparano, Francesca, Ciardiello, Fortunato, and Morgillo, Floriana

Subjects
0301 basic medicine, medicine.medical_treatment, Review, medicine.disease_cause, Catalysis, Inorganic Chemistry, Cell therapy, lcsh:Chemistry, 03 medical and health sciences, 0302 clinical medicine, Immune system, Cancer immunotherapy, Neoplasms, Animals, Humans, Medicine, cancer, HGF, Physical and Theoretical Chemistry, Molecular Biology, lcsh:QH301-705.5, Spectroscopy, Hepatocyte Growth Factor, business.industry, Organic Chemistry, Cancer, General Medicine, Immunotherapy, Proto-Oncogene Proteins c-met, medicine.disease, Computer Science Applications, immune system, 030104 developmental biology, lcsh:Biology (General), lcsh:QD1-999, Tumor progression, 030220 oncology & carcinogenesis, Cancer research, MET, Hepatocyte growth factor, immunotherapy, business, Carcinogenesis, medicine.drug
Abstract

An overactivation of hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) axis promotes tumorigenesis and tumor progression in various cancer types. Research data recently evidenced that HGF/MET signaling is also involved also in the immune response, mainly modulating dendritic cells functions. In general, the pathway seems to play an immunosuppressive role, thus hypothesizing that it could constitute a mechanism of primary and acquired resistance to cancer immunotherapy. Recently, some approaches are being developed, including drug design and cell therapy to combine MET and programmed cell death receptor-1 (PD-1)/programmed cell death receptor-ligand 1 (PD-L1) inhibition. This approach could represent a new weapon in cancer therapy in the future.

Published
2018

19. PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer.

Author

De Rosa C, Iommelli F, De Rosa V, Ercolano G, Sodano F, Tuccillo C, Amato L, Tirino V, Ariano A, Cimmino F, di Guida G, Filosa G, di Liello A, Ciardiello D, Martinelli E, Troiani T, Napolitano S, Martini G, Ciardiello F, Papaccio F, Morgillo F, and Della Corte CM

Abstract

Background: Lung cancer (LC), including both non-small (NSCLC) and small (SCLC) subtypes, is currently treated with a combination of chemo- and immunotherapy. However, predictive biomarkers to identify high-risk patients are needed. Here, we explore the role of peripheral blood mononuclear cells (PBMCs) as a tool for novel biomarkers searching., Methods: We analyzed the expression of the cGAS-STING pathway, a key DNA sensor that activates during chemotherapy, in PBMCs from LC patients divided into best responders (BR), responders (R) and non-responders (NR). The PBMCs were whole exome sequenced (WES)., Results: PBMCs from BR and R patients of LC cohorts showed the highest levels of STING ( p < 0.0001) and CXCL10 ( p < 0.0001). From WES, each subject had at least 1 germline/somatic alteration in a DDR gene and the presence of more DDR gene mutations correlated with clinical responses, suggesting novel biomarker implications. Thus, we tested the effect of the pharmacological DDR inhibitor (DDRi) in PBMCs and in three-dimensional spheroid co-culture of PBMCs and LC cell lines; we found that DDRi strongly increased cGAS-STING expression and tumor infiltration ability of immune cells in NR and R patients. Furthermore, we performed FACS analysis of PBMCs derived from LC patients from the BR, R and NR cohorts and we found that cytotoxic T cell subpopulations displayed the highest STING expression., Conclusions: cGAS-STING signaling activation in PBMCs may be a novel potential predictive biomarker for the response to immunotherapy and high levels are correlated with a better response to treatment along with an overall increased antitumor immune injury.

Published
2024
Full Text
View/download PDF

20. Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer.

Author

Della Corte CM, Fasano M, Papaccio F, Ciardiello F, and Morgillo F

Abstract

The Hepatocyte growth factor (HGF)-mesenchymal-epithelial transition (MET) pathway is deregulated in several cancers and is associated with aggressive phenotype and worse prognosis. MET, a tyrosine kinase receptor activated by HGF, plays a physiological role in embryogenesis, promoting cell growth, survival and motility. HGF-MET aberrant activation in tumorigenesis acts through various mechanisms: paracrine/autocrine HGF production, MET overexpression, MET germ-line and sporadic mutations and cross-talk with other growth factor receptors. In addition, MET activation could represent a mechanism of escape from other targeted therapies, through receptor amplification or over-stimulation by the ligand, as demonstrated in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) models with acquired resistance to epidermal growth factor receptor (EGFR) inhibitors and also in models of melanoma resistant to the BRAF inhibitor vemurafenib. As a consequence, a lot of molecules targeting MET signaling are under clinical investigation as single agent or in combination with other targeted drugs. Patient selection, based on MET expression on tumor samples (eventually, by re-biopsy of new metastatic sites), and pharmacokinetic/pharmacodynamic markers are needed. Authors review the latest data on the role of MET and the molecular mechanism underlying primary or acquired resistance to biological agents, focusing on NSCLC, CRC and melanoma.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results